These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2055727)

  • 21. Comparison of Gd-BOPTA with Gd-DTPA in MR imaging of rat liver.
    Pavone P; Patrizio G; Buoni C; Tettamanti E; Passariello R; Musu C; Tirone P; Felder E
    Radiology; 1990 Jul; 176(1):61-4. PubMed ID: 2353112
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and characterization of nonionic paramagnetic metal complexes as potential magnetic resonance imaging contrast agents.
    White DH; Rajagopalan R; Kuan KT; Lin Y; Wallace RA; Rogic MM; Bosworth ME; Robbins MS; Ralston WH; Adams MD
    Invest Radiol; 1990 Sep; 25 Suppl 1():S56-7. PubMed ID: 2126534
    [No Abstract]   [Full Text] [Related]  

  • 23. The relationship between thermodynamics and the toxicity of gadolinium complexes.
    Cacheris WP; Quay SC; Rocklage SM
    Magn Reson Imaging; 1990; 8(4):467-81. PubMed ID: 2118207
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute cardiotoxicity of gadolinium-based contrast media: findings in the isolated rat heart.
    Akre BT; Dunkel JA; Hustvedt SO; Refsum H
    Acad Radiol; 1997 Apr; 4(4):283-91. PubMed ID: 9110026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of magnetic resonance imaging contrast agents.
    Shellock FG; Kanal E
    J Magn Reson Imaging; 1999 Sep; 10(3):477-84. PubMed ID: 10508312
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of liver capillary permeability using a macromolecular contrast agent for magnetic resonance imaging.
    Clément O; Vuillemin-Bodaghi V; Cuénod CA; Siauve N; Blustajn J; Frija G
    Acad Radiol; 1996 Aug; 3 Suppl 2():S342-3. PubMed ID: 8796598
    [No Abstract]   [Full Text] [Related]  

  • 27. Contrast media-induced renal tubular vacuolization. A light and electron microscopic study on rat kidneys.
    Tervahartiala P; Kivisaari L; Kivisaari R; Virtanen I; Standertskjöld-Nordenstam CG
    Invest Radiol; 1991 Oct; 26(10):882-7. PubMed ID: 1960030
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety profiles of gadolinium chelates in juvenile rats differ according to the risk of dissociation.
    Fretellier N; Maazouz M; Luseau A; Baudimont F; Jestin-Mayer G; Bourgery S; Rasschaert M; Bruneval P; Factor C; Mecieb F; Idée JM; Corot C
    Reprod Toxicol; 2014 Dec; 50():171-9. PubMed ID: 25462783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
    Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subchronic toxicity of the gadolinium chelates.
    Runge VM; Kuehl TJ; Jackson CB; Estrada EA
    Acad Radiol; 2005 May; 12 Suppl 1():S6-9. PubMed ID: 16106537
    [No Abstract]   [Full Text] [Related]  

  • 31. Renal tolerance of gadolinium-DOTA and gadolinium-DTPA in rats.
    Brillet G; Dubois M; Beaufils H; Bourbouze R; Deray G
    Invest Radiol; 1994 Mar; 29(3):352-4. PubMed ID: 8175311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental approach to the intra-arterial magnetic resonance imaging contrast media (Gd-DTPA-iodized oil) and new lipophilic gadolinium complex combined with iodized oil.
    Yoshikawa K; Shiono T; Yamashita T; Iwai H; Abe O; Hisamatsu K; Takenaka E
    Invest Radiol; 1994 Jun; 29 Suppl 2():S245-6. PubMed ID: 7928246
    [No Abstract]   [Full Text] [Related]  

  • 33. Triple-dose versus standard-dose gadopentetate dimeglumine: a randomized study in 199 patients.
    Haustein J; Laniado M; Niendorf HP; Louton T; Beck W; Planitzer J; Schöffel M; Reiser M; Kaiser W; Schörner W
    Radiology; 1993 Mar; 186(3):855-60. PubMed ID: 8430199
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent.
    Weinmann HJ; Brasch RC; Press WR; Wesbey GE
    AJR Am J Roentgenol; 1984 Mar; 142(3):619-24. PubMed ID: 6607655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental trials with Gd(DO3A)--a nonionic magnetic resonance contrast agent.
    Runge VM; Kaufman DM; Wood ML; Adelman LS; Jacobson S
    Int J Rad Appl Instrum B; 1989; 16(6):561-7. PubMed ID: 2606711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Histologic abnormalities associated with gadolinium enhancement on MR in the initial hours of experimental cerebral infarction.
    Mathews VP; Monsein LH; Pardo CA; Bryan RN
    AJNR Am J Neuroradiol; 1994 Mar; 15(3):573-9. PubMed ID: 8197960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clearance of liposomal gadolinium: in vivo decomplexation.
    Unger EC; Fritz TA; Tilcock C; New TE
    J Magn Reson Imaging; 1991; 1(6):689-93. PubMed ID: 1823174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of gadolinium-based contrast agents on the growth of fish cells lines.
    Parant M; Sohm B; Flayac J; Perrat E; Chuburu F; Cadiou C; Rosin C; Cossu-Leguille C
    Ecotoxicol Environ Saf; 2019 Oct; 182():109385. PubMed ID: 31260918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contrast media-induced renal morphologic lesions during experimental hemorrhagic necrotizing pancreatitis.
    Tervahartiala P; Kivisaari L; Kivisaari R; Virtanen I
    Invest Radiol; 1992 Dec; 27(12):1064-8. PubMed ID: 1473926
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gadodiamide injection. First human experience with the nonionic magnetic resonance imaging enhancement agent.
    Van Wagoner M; Worah D
    Invest Radiol; 1993 Mar; 28 Suppl 1():S44-8. PubMed ID: 8486503
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.